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Abstract 
Abstract: Ghrelin is a peptide hormone that was originally isolated from the stomach as the 
endogenous ligand for the growth hormone secretagogue receptor (GHSR). Ghrelin has many 
functions, including the regulation of appetite and gut motility, growth hormone release from 
the anterior pituitary and roles in the cardiovascular and immune systems. Ghrelin and its 
receptor are expressed in a number of cancers and cancer cell lines and may play a role in 
processes associated with cancer progression, including cell proliferation, apoptosis, and cell 
invasion and migration.  
 
 
  
3 
 
1.0 Introduction  
Ghrelin is a multifunctional peptide hormone originally isolated from the stomach as the 
endogenous ligand for the growth hormone secretagogue receptor (GHSR) (Kojima et al., 
1999). Ghrelin has a number of functions, including roles in the regulation of growth 
hormone release, metabolism, appetite, the cardiovascular system and insulin secretion 
(Kojima et al., 1999). There is also growing evidence that ghrelin plays an 
autocrine/paracrine role in a number of processes related to cancer progression, including cell 
proliferation (Jeffery et al., 2002; Jeffery et al., 2003), cell migration (Dixit et al., 2006), and 
apoptosis (Fung et al., 2010). This review will focus on the autocrine/paracrine role of ghrelin 
in cancer, and the actions of ghrelin that may promote cancer progression.  
 
2.0 Paracrine/autocrine ghrelin 
2.1 Local expression of the ghrelin-axis 
While ghrelin was originally discovered in the rat and human stomach (Kojima et al., 1999), 
the expression of ghrelin and its receptor, the growth hormone secretagogue receptor (GHSR), 
has been demonstrated in a range of tissues. This includes the small and large intestine, the 
hypothalamus and pituitary (Korbonits et al., 2001) and a number of other peripheral tissues, 
including the endocrine pancreas (Volante et al., 2002) and placenta (Gualillo et al., 2001). 
Local production of ghrelin has been shown in a range of cancers including pituitary 
adenomas (Kim et al., 2001; Korbonits et al., 2001; Wasko et al., 2006; Wasko et al., 2008), 
and colorectal (Papotti et al., 2001; Waseem et al., 2008), gastric (An et al., 2007; Aydin et 
al., 2005; Ekeblad et al., 2006; Papotti et al., 2001), prostate (Cassoni et al., 2004; Jeffery et 
al., 2002; Yeh et al., 2005), breast (Jeffery et al., 2005), thyroid (Volante et al., 2003), 
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endocrine pancreatic (Ekeblad et al., 2007; Iwakura et al., 2002; Volante et al., 2002), ovarian 
(Gaytan et al., 2005), endometrial (Fung et al., 2010), testicular (Gaytan et al., 2004), 
adrenocortical (Ueberberg et al., 2008), renal (Dagli et al., 2009) and lung cancer (Cassoni et 
al., 2006).  Ghrelin is highly expressed in the stomach and ghrelin secretion is greatly reduced 
in atrophic gastritis associated with Helicobacter pylori infection, as ghrelin-producing cells 
are damaged in this precancerous condition (Zub-Pokrowiecka et al., 2010).  Treatment for 
gastric cancer, where the whole stomach is removed, therefore, greatly reduces plasma 
ghrelin levels (Zub-Pokrowiecka et al., 2010).    
 
The growth hormone secretagogue receptor (GHSR) isoforms, GHSR 1a and GHSR 1b, are 
also widely expressed (Gnanapavan et al., 2002; Ueberberg et al., 2009). Many of the 
endocrine functions of ghrelin appear to be mediated by the GHSR 1a isoform, which is 
known as the functional ghrelin receptor. GHSR 1a expression was initially characterised in 
the pituitary and the hypothalamus (Howard et al., 1996) and it is also expressed in numerous 
peripheral tissues including the stomach, intestine, pancreas, spleen, thyroid, gonads, adrenal 
gland, kidney, heart, lung, liver, adipose tissue, bone and prostate (Camina, 2006; 
Gnanapavan et al., 2002; Jeffery et al., 2002; Kojima et al., 2005; Soares et al., 2008). The 
GHSR is expressed in a range of tumours, including pituitary tumours, prostate, breast and 
ovarian cancer and in astrocytoma (Adams et al., 1998; Dixit et al., 2006; Gaytan et al., 2005; 
Jeffery et al., 2002; Jeffery et al., 2005; Korbonits et al., 1998; Skinner et al., 1998). GHSR 
1a expression is absent in some cases of colorectal cancer, adrenocortical tumours, non-small 
cell lung cancer, leukaemia and some breast cancer cell lines (Barzon et al., 2005; Cassoni et 
al., 2001; Ghe et al., 2002; Takahashi et al., 2006). GHSR1a expression is not required for all 
ghrelin functions, however, and many of the effects of ghrelin could be mediated by an 
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alternative receptor that has not yet been identified (for review, see Seim et al. in this special 
issue). 
 
The truncated, 5-transmembrane domain, ghrelin receptor isoform, GHSR 1b, is believed to 
be a non-functional isoform of the receptor (Howard et al., 1996; Kojima et al., 1999). In a 
number of cancers, GHSR 1a expression is downregulated or absent (Barzon et al., 2005; 
Cassoni et al., 2001; Ghe et al., 2002; Takahashi et al., 2006), while the non-functional, 
truncated form of the receptor, GHSR 1b is widely expressed in cancer and expression may 
be upregulated compared to normal tissues (Waseem et al., 2008).   
 
2.2 Paracrine/autocrine actions of the ghrelin axis in cancer progression 
2.2.1 Ghrelin in cell proliferation 
As ghrelin is synthesised locally in many tissues, it could act as an autocrine/paracrine 
growth factor in normal and cancer tissues (Jeffery et al., 2002). While most studies indicate 
that ghrelin stimulates cell proliferation in normal cell lines (Andreis et al., 2003; 
Maccarinelli et al., 2005; Nanzer et al., 2004; Pettersson et al., 2002; Wang et al., 2009; Xia 
et al., 2004), the effect of ghrelin in cancer cell lines has proven more controversial.  
 
Ghrelin may act as a growth factor in a range of cancers and increase cell proliferation, a 
hallmark of cancer (Hanahan et al., 2000; Jeffery et al., 2003; Soares et al., 2008). Ghrelin 
stimulates proliferation in a number of cancer cell lines, including the HepG2 human 
hepatoma cell line (Murata et al., 2002), human erythroleukaemic (De Vriese et al., 2005), 
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and leukaemic cell lines (De Vriese et al., 2008), in adrenocortical carcinoma (Barzon et al., 
2005), in pancreatic adenocarcinoma cell lines (Duxbury et al., 2003), colorectal cancer 
(Waseem et al., 2008), the JEG-3 choriocarcinoma cell line (Rak-Mardyla et al., 2010) and in 
prostate (Jeffery et al., 2002; Yeh et al., 2005), breast (Jeffery et al., 2005) and endometrial 
cell lines (Fung et al., 2010). Ghrelin-induced proliferation is mediated by the ERK1/2 
MAPK pathway in a number of cell lines, including prostate cancer cells lines (Yeh et al., 
2005), the rat normal pituitary-derived GH3 cell-line (Nanzer et al., 2004), and the rat 
thyrocyte FRTL-5 cell line (Park et al., 2008).  
 
While a number of studies have demonstrated that ghrelin stimulates cell proliferation, some 
reports indicate that ghrelin may inhibit proliferation. This includes thyroid (Volante et al., 
2003), prostate (Diaz-Lezama et al., 2010) and breast cancer (Cassoni et al., 2001) and small 
cell lung carcinoma (Cassoni et al., 2006) cell lines. Studies in the ARO anaplastic thyroid 
carcinoma and the N-PAP papillary follicular thyroid carcinoma cell lines demonstrated a 
modest inhibition of cell growth using crystal violet staining-based assay (Volante et al., 
2003). In the N-PAP cell line, a statistically significant decrease in cell proliferation was seen 
with 100nM and 1M concentrations of ghrelin after 96 hours. In the ARO cell line, a 
significant decrease in cell number was only seen with 1M ghrelin treatments and no effect 
was seen in cells treated with 10nM ghrelin (Volante et al., 2003). In contrast, no change in 
cell proliferation was seen in the ARO cell line treated with ghrelin, or in this cell line 
stimulated with thyroid stimulating hormone in another study (Park et al., 2008). It is unclear 
if ghrelin was replenished during the assay in these studies.  
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The role of ghrelin in stimulating cell proliferation in prostate cancer remains controversial. 
Studies performed by our research group have shown that ghrelin stimulates proliferation of 
the PC-3 prostate cancer cell line at levels within the physiological range (5-10nM) using a 
metabolic, colourimetric MTT assay  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) to estimate changes in cell number (Jeffery et al., 2002; Yeh et al., 2005). A similar 
response in the PC3 cell line has been reported, where low concentrations of ghrelin (10-
100pM) stimulated cell proliferation, but higher concentrations (1M) inhibited proliferation 
(Cassoni et al., 2004). In contrast, a recent study demonstrated that ghrelin treatment (10-
50nM) decreased the incorporation of 3H thymidine in the PC3 cell line, indicating that it 
decreased cell proliferation (Diaz-Lezama et al., 2010). Ghrelin treatment stimulated an 
increase in intracellular free calcium and the decrease in cell number was inhibited by 
treatment with T-type calcium channel blockers (Diaz-Lezama et al., 2010). We have also 
demonstrated that ghrelin stimulates cell proliferation in the LNCaP prostate cancer cell line 
(Yeh et al., 2005). In contrast to our findings, Cassoni et al., 2004 demonstrated no effect on 
LNCaP prostate cancer cell line proliferation. In the androgen-independent DU145 prostate 
cancer cell line, ghrelin and des-ghrelin alone had no effect on cell proliferation (measured by 
3H thymidine incorporation), but they inhibited cell proliferation stimulated by IGF-I 
treatment (Cassoni et al., 2004).  
 
Although the reasons for these discrepancies are not immediately apparent, these studies 
varied in the concentrations of ghrelin used and in the assay method applied. The application 
of supraphysiological doses of ghrelin could have an inhibitory effect, while physiological 
levels could stimulate cell proliferation (Lanfranco et al., 2008; Nikolopoulos et al., 2010). In 
our assays, ghrelin was replenished every 24 hours, while Cassoni et al., treated the cells with 
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ghrelin every 48 hours. Ghrelin has been reported to have a short half- life and it is rapidly 
de-acetylated and also protelytically cleaved (De Vriese et al., 2004; Hosoda et al., 2004) and 
therefore, chronic ghrelin treatments require the frequent addition of ghrelin to the media. 
 
There is also conflicting data regarding the effect of ghrelin on breast cancer cell proliferation, 
with studies demonstrating either proliferative or anti-proliferative effects. Cassoni et al., 
(2001) demonstrated that ghrelin treatment (1M) significantly decreased cell number after 
48 or 96 hours of treatment in the oestrogen-dependent MCF7 breast cancer cell line and the 
oestrogen-independent MDA-MB 231 cell line. This study was performed using cell counting 
after cells were stained with crystal violet (Cassoni et al., 2001). They also demonstrated that 
ghrelin and desacyl ghrelin inhibited serum-stimulated 3H thymidine incorporation after 20 
hours of treatment with a range of concentrations of ghrelin (Cassoni et al., 2001). This effect 
was not seen with the MDA-MB231 cell line or in oestrogen-stimulated MCF7 cells, unless 
concentrations of more than 1-2M ghrelin were applied (Cassoni et al., 2001). In contrast, 
we have demonstrated that ghrelin stimulates cell proliferation in the MDA-MB-231, and the 
MDA-MB-435 breast cancer cell lines, but ghrelin had no significant effect on cell 
proliferation in the MCF7 or the normal-derived MCF10A cell line (Jeffery et al., 2005). The 
origin of the MDA-MB435 cell line is currently controversial, however, with suggestions that 
it is actually derived from a melanoma rather than breast cancer (Chambers, 2009). Cassoni et 
al., (2001) found that GHSR 1a was not expressed in the MDA-MB231 and MCF7 breast 
cancer cell lines using RT-PCR, suggesting that the anti-proliferative effects of ghrelin could 
be mediated by an alternative receptor. The inhibitory effects of ghrelin in breast cancer cell 
lines occurs at high ghrelin concentrations, as reported in studies in thyroid and prostate 
cancer cell lines (Cassoni et al., 2001; Volante et al., 2003). In pancreatic cancer cell lines, an 
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increase in proliferation was seen at lower ghrelin concentrations and this effect decreased at 
higher concentrations (Duxbury et al., 2003). 
 
Both ghrelin and des-ghrelin inhibited cell proliferation in the H345 small cell lung cancer 
cell line (Cassoni et al., 2006). In contrast, in the Calu-1 lung epidermoid carcinoma cell line, 
ghrelin treatment (1nM-2M) had no significant effect on cell proliferation after 24 hours 
(Ghe et al., 2002). In this cell line, however, synthetic peptide analogues of ghrelin, hexarelin 
and EP-80317, inhibited both basal proliferation and insulin like growth factor (IGF)-II 
stimulated proliferation in a dose-dependent manner (Ghe et al., 2002). As these lung cell 
lines do not express GHSR 1a, these effects are likely to be mediated by an alternative 
ghrelin receptor (Cassoni et al., 2006; Ghe et al., 2002). 
 
Desacyl ghrelin also stimulates cell proliferation in some cell lines. As desacyl ghrelin does 
not activate the GHSR 1a at physiological doses, it presumably acts through an unidentified 
alternative ghrelin receptor. Desacyl ghrelin and ghrelin have similar proliferative effects in 
the rat GH3 somatotroph cell line, and in the SW-13 and NCI-H295R adrenocortical tumour 
cell lines, and this suggests that these effects are not mediated by GHSR 1a (Delhanty et al., 
2007; Nanzer et al., 2004).  
 
2.2.2 Ghrelin and apoptosis 
Ghrelin protects against basal or induced apoptosis in a number of normal cell types, 
including cardiomyocytes, vascular smooth muscle cells and endothelial cells (Baldanzi et al., 
2002; Kui et al., 2009), adrenocortical cells (Mazzocchi et al., 2004), adipocytes (Kim et al., 
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2004), mouse osteoblastic MC3T3-E1 cells (Kim et al., 2005), -pancreatic islet  cells 
(Granata et al., 2007; Zhang et al., 2007) and hypothalamic neuronal cells (Chung et al., 
2007). In the H9c2 cardiomyocyte and PAE (porcine aortic) endothelial cell lines, ghrelin and 
desacyl ghrelin protect against apoptosis, with ghrelin signaling through the ERK1/2 and 
PI3K/Akt pathways (Baldanzi et al., 2002). These effects are likely to be mediated through 
the alternative ghrelin receptor, as H9c2 cells do not express GHSR 1a (Baldanzi et al., 2002).  
 
Fewer studies have investigated the role of ghrelin in regulating apoptosis in cancer, however. 
Recently, ghrelin treatment has been demonstrated to protect against apoptosis in endometrial 
cancer cell lines in response to treatment with the apoptosis-inducing agent doxorubicin 
(Fung et al., 2010). Ghrelin inhibits apoptosis through a range of mechanisms. In the rat PC-
12 phaeochromocytoma cell line (derived from an adrenal medullary tumour) ghrelin protects 
against apoptosis by inhibiting the activation of ASK1 (apoptosis signal regulating kinase 1) 
by inducing Hsp70 (heat shock protein) (Yang et al., 2007). ASK1 is a component of the 
MAPK signalling pathway and plays a role in stimulating apoptosis in response to a range of 
apoptosis-inducing agents (Yang et al., 2007). In one study in the SW-13 adrenocortical 
carcinoma cell line, ghrelin treatment reduced basal apoptosis by 15-20% and caspase 3/7 
activity was also downregulated (Delhanty et al., 2007). In this study, desacyl ghrelin had a 
more pronounced protective effect than acylated ghrelin. In contrast, Belloni et al., (2004) 
described a marked increase in the basal apoptotic rate in the SW-13 and NCI-H295 
adrenocortical carcinoma cell lines and in primary aldosteroma cells (Belloni et al., 2004). 
These authors suggested that by promoting apoptosis, ghrelin may have useful anti-tumour 
actions (Belloni et al., 2004). Pro-apoptotic effects have also been described in the H345 
small cell lung carcinoma cell line (Cassoni et al., 2006), and in the PC3 prostate cancer cell 
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line, where ghrelin also decreased the rate of cell proliferation (Diaz-Lezama et al., 2010). 
This pro-apoptotic effect was thought to be mediated by signalling through T-type calcium 
channels (Diaz-Lezama et al., 2010). Ghrelin was not pro-apoptotic in oesophageal 
adenocarcinoma cells treated with a number of apoptosis-inducing agents, nor did it protect 
against apoptosis (Konturek et al., 2008). As the majority of studies have reported that 
ghrelin has an anti-apoptotic effect, ghrelin may, therefore, protect against apoptosis in some 
cell types and be pro-apoptotic in others. The effects of ghrelin on apoptosis could also vary 
with the apoptosis-inducing agents and assay methods used in these studies.  
 
 
 
2.2.3 Ghrelin in cell migration and invasion 
Ghrelin may also have a role in promoting cell motility and invasion in a number of cancers. 
Human astrocytoma cell lines secrete ghrelin, and ghrelin treatment increases their rate of cell 
migration in scratch assays and Transwell migration assays (Dixit et al., 2006). Ghrelin also 
stimulates cell invasion in a dose-dependent manner (Dixit et al., 2006). 
  
Finally, ghrelin increases cell proliferation, migration and invasion in pancreatic cancer cell 
lines (Duxbury et al., 2003). Invasion and migration in response to ghrelin treatment occurred 
through the activation of the PI3K/Akt pathway, a pathway which is often associated with an 
increase in cell motility and invasion (Duxbury et al., 2003). The effects of ghrelin on cell 
motility may also be mediated through an alternative ghrelin receptor. In colorectal cell lines, 
autocrine ghrelin appears to stimulate cell invasion and migration, and these processes can be 
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almost abolished in assays where cells are treated with the ghrelin antagonist, D(Lys-3)-
GHRP-6, or by a ghrelin neutralising antibody (Waseem et al., 2008).  
 
3.0 Conclusion  
Ghrelin is expressed in a wide range of cancer tissues and plays a role in a number of key 
processes in cancer progression, including cell proliferation, cell migration and invasion, and 
apoptosis. As there have been a number of conflicting reports, it is currently unclear whether 
ghrelin promotes cancer or inhibit its development and it is possible that it could have both 
stimulatory and inhibitory effects. In most cell lines, ghrelin stimulates cell proliferation and 
is anti-apoptotic, and these effects could combine to promote cancer progression. Although 
there have been few studies, ghrelin appears to increase cell migration and invasion, 
processes which are important in cancer metastasis and spread. While further studies are 
required to establish the role of ghrelin in cancer development, there is evidence to suggest 
that ghrelin should be used with caution as a therapeutic to stimulate growth hormone release 
or for the treatment of cancer cachexia.  
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Figure legend 
Figure 1: Ghrelin plays roles in a number of processes related to cancer progression, 
including proliferation, apoptosis, and cell invasion and migration  
